# Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant

> **NCT03328936** · PHASE2 · WITHDRAWN · sponsor: **Ohio State University Comprehensive Cancer Center**

## Conditions studied

- Hematopoietic Cell Transplantation Recipient
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Melphalan Hydrochloride
- **DRUG:** Melphalan Hydrochloride
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT03328936
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-09-01
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2020-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03328936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03328936, "Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03328936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*